Alogliptin

Research use only, not for human use.

Alogliptin(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10, 000-fold selectivity over DPP-8 and DPP-9.

Alogliptin is a DPP-4 inhibitor used for the treatment of Type 2 diabetes. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.

Alogliptin

Chromatin/Epigenetic

Sirtuin

DPP-4

Metabolic Disease

——

850649-61-5

339.39

C18H21N5O2

98%

——

CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=CC=CC=C2C#N)C1=O

(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

(-20℃)

With Ice Pack

≥ 2 years